Emergent BioSolutions Inc.
EBS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.06 | -0.00 | 0.03 |
| FCF Yield | -1.21% | 29.93% | -5.60% | -15.75% |
| EV / EBITDA | 9.22 | 31.76 | 10.39 | 51.54 |
| Quality | ||||
| ROIC | 5.13% | 0.09% | 2.79% | -0.88% |
| Gross Margin | 60.32% | 43.08% | 53.74% | 70.11% |
| Cash Conversion Ratio | -0.04 | -8.87 | -0.16 | 2.55 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.57% | -7.39% | -0.31% | -2.25% |
| Free Cash Flow Growth | -105.51% | 799.32% | 81.86% | -155.17% |
| Safety | ||||
| Net Debt / EBITDA | 4.34 | 17.04 | 6.87 | 26.87 |
| Interest Coverage | 5.03 | 0.11 | 3.39 | -0.64 |
| Efficiency | ||||
| Inventory Turnover | 0.26 | 0.24 | 0.33 | 0.19 |
| Cash Conversion Cycle | 351.58 | 359.46 | 306.54 | 459.25 |